Skip to main content
. 2019 Feb 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798

Figure 1.

Figure 1

Systematic review and network meta-analyses study selection flow chart. *45 studies reporting outcomes at week 24 and one study reporting outcome at week 52. csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IR, inadequate responders; NMA, network meta-analyses; TNFi, tumour necrosis factor α inhibitors.